184 related articles for article (PubMed ID: 15701266)
1. Impact of elapsed treatment time on outcome of external-beam radiation therapy for localized carcinoma of the prostate.
Perez CA; Michalski J; Mansur D; Lockett MA
Cancer J; 2004; 10(6):349-56. PubMed ID: 15701266
[TBL] [Abstract][Full Text] [Related]
2. Chemical disease-free survival in localized carcinoma of prostate treated with external beam irradiation: comparison of American Society of Therapeutic Radiology and Oncology Consensus or 1 ng/mL as endpoint.
Perez CA; Michalski JM; Lockett MA
Int J Radiat Oncol Biol Phys; 2001 Apr; 49(5):1287-96. PubMed ID: 11286836
[TBL] [Abstract][Full Text] [Related]
3. Nonrandomized evaluation of pelvic lymph node irradiation in localized carcinoma of the prostate.
Perez CA; Michalski J; Brown KC; Lockett MA
Int J Radiat Oncol Biol Phys; 1996 Oct; 36(3):573-84. PubMed ID: 8948341
[TBL] [Abstract][Full Text] [Related]
4. Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: preliminary results of a nonrandomized comparison.
Perez CA; Michalski JM; Purdy JA; Wasserman TH; Williams K; Lockett MA
Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):629-37. PubMed ID: 10837945
[TBL] [Abstract][Full Text] [Related]
5. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
6. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
[TBL] [Abstract][Full Text] [Related]
7. Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy.
Perez CA; Hanks GE; Leibel SA; Zietman AL; Fuks Z; Lee WR
Cancer; 1993 Dec; 72(11):3156-73. PubMed ID: 7694785
[TBL] [Abstract][Full Text] [Related]
8. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer.
Galalae RM; Kovács G; Schultze J; Loch T; Rzehak P; Wilhelm R; Bertermann H; Buschbeck B; Kohr P; Kimmig B
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):81-90. PubMed ID: 11777625
[TBL] [Abstract][Full Text] [Related]
10. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
11. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
Stock RG; Stone NN
Brachytherapy; 2002; 1(1):2-10. PubMed ID: 15062181
[TBL] [Abstract][Full Text] [Related]
12. Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer.
Kupelian PA; Mohan DS; Lyons J; Klein EA; Reddy CA
Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):567-74. PubMed ID: 10701735
[TBL] [Abstract][Full Text] [Related]
13. Technical and tumor-related factors affecting outcome of definitive irradiation for localized carcinoma of the prostate.
Perez CA; Lee HK; Georgiou A; Logsdon MD; Lai PP; Lockett MA
Int J Radiat Oncol Biol Phys; 1993 Jul; 26(4):581-91. PubMed ID: 8330986
[TBL] [Abstract][Full Text] [Related]
14. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
[TBL] [Abstract][Full Text] [Related]
15. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer.
Martinez AA; Gustafson G; Gonzalez J; Armour E; Mitchell C; Edmundson G; Spencer W; Stromberg J; Huang R; Vicini F
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):316-27. PubMed ID: 12023135
[TBL] [Abstract][Full Text] [Related]
16. Three-dimensional conformal therapy versus standard radiation therapy in localized carcinoma of prostate: an update.
Perez CA; Michalski JM; Mansur D; Lockett MA
Clin Prostate Cancer; 2002 Sep; 1(2):97-104. PubMed ID: 15046700
[TBL] [Abstract][Full Text] [Related]
17. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
18. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
19. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect?
Khuntia D; Reddy CA; Mahadevan A; Klein EA; Kupelian PA
Cancer; 2004 Mar; 100(6):1283-92. PubMed ID: 15022298
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis.
Livsey JE; Cowan RA; Wylie JP; Swindell R; Read G; Khoo VS; Logue JP
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1254-9. PubMed ID: 14630259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
